The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of alemtuzumab (ALZ) in combination with dose-adjusted EPOCH (DA-EPOCH) in untreated nodal peripheral T-cell lymphoma (PTCL).
Cliona Grant
No relevant relationships to disclose
Kieron Dunleavy
No relevant relationships to disclose
John E. Janik
No relevant relationships to disclose
Margaret Shovlin
No relevant relationships to disclose
Seth M. Steinberg
No relevant relationships to disclose
Francesco D'Amore
Research Funding - Genzyme
Maryalice Stetler-Stevenson
No relevant relationships to disclose
Stefania Pittaluga
No relevant relationships to disclose
Elaine S. Jaffe
No relevant relationships to disclose
Wyndham Hopkins Wilson
No relevant relationships to disclose